Onychomysosis - Onikomikożi
☆ Fir-riżultati ta' Stiftung Warentest tal-2022 mill-Ġermanja, is-sodisfazzjon tal-konsumatur b'ModelDerm kien biss ftit inqas milli b'konsultazzjonijiet bit-telemediċina mħallsa.
Dwiefer tas-sieq affettwat minn Onikomikożi (Onychomysosis)
Sieq ta 'persuna b'infezzjoni fungali tad-dwiefer għaxar ġimgħat f'kors ta' medikazzjoni orali terbinafine. Innota l-faxxa ta 'tkabbir tad-dwiefer b'saħħtu wara l-imsiemer infettati li fadal.
References
L-antifungali sistemiċi huma l-aktar trattament effettiv. Meta-analiżi turi rati ta' kura mikotika kif ġej: terbinafine = 76%, itraconazole with pulse dosing = 63%, itraconazole with continuous dosing = 59%, fluconazole =48% . Debridement konkomitanti tad-dwiefer ikompli jżid ir-rati ta 'fejqan. Terapija topika b' ciclopirox hija inqas effettiva; għandu rata ta 'falliment li taqbeż is-60%.
Systemic antifungals are the most effective treatment. Meta-analyses shows mycotic cure rates as follows: terbinafine = 76%, itraconazole with pulse dosing = 63%, itraconazole with continuous dosing = 59%, fluconazole =48%. Concomitant nail debridement further increases cure rates. Topical therapy with ciclopirox is less effective; it has a failure rate exceeding 60%.
Systemic antifungals are the most effective treatment. Meta-analyses shows mycotic cure rates as follows: terbinafine = 76%, itraconazole with pulse dosing = 63%, itraconazole with continuous dosing = 59%, fluconazole =48%. Concomitant nail debridement further increases cure rates. Topical therapy with ciclopirox is less effective; it has a failure rate exceeding 60%.
Onychomycosis hija infezzjoni fungali li taffettwa d-dwiefer. Meta tkun ikkawżata minn dermatophytes, tissejjaħ tinea unguium. Onychomycosis tinkludi infezzjonijiet ikkawżati minn dermatofiti, ħmira, u moffa. Problema tad-dwiefer mhux ikkawżata minn infezzjoni fungali tissejjaħ nail dystrophy. Għalkemm jista 'jaffettwa kemm id-dwiefer tas-swaba' kif ukoll id-dwiefer tas-swaba ', l-onikomikożi tad-dwiefer tas-swaba' hija aktar komuni. Dan l-artikolu jiddiskuti diversi aspetti ta 'onychomycosis toenail, bħall-impatt tagħha, tipi kliniċi, stadji, dijanjosi, u trattament. Filwaqt li ma tkunx ta’ theddida għall-ħajja, l-onikomikożi tista’ twassal għal kumplikazzjonijiet serji bħal ċellulite, sepsis, infezzjoni fl-għadam, ħsara fit-tessuti u telf tad-dwiefer.
Onychomycosis is a fungal infection of the nail unit. When dermatophytes cause onychomycosis, this condition is called tinea unguium. The term onychomycosis encompasses the dermatophytes, yeasts, and saprophytic mold infections. An abnormal nail not caused by a fungal infection is a dystrophic nail. Onychomycosis can infect both fingernails and toenails, but onychomycosis of the toenail is much more prevalent. Discussed in detail in this activity are all evolving facets of the topic, including disease burden, clinical types, staging, diagnosis, and management of toenail onychomycosis. While non-life-threatening, onychomycosis can lead to severe complications such as cellulitis, sepsis, osteomyelitis, tissue damage, and nail loss.
Onychomycosis is a fungal infection of the nail unit. When dermatophytes cause onychomycosis, this condition is called tinea unguium. The term onychomycosis encompasses the dermatophytes, yeasts, and saprophytic mold infections. An abnormal nail not caused by a fungal infection is a dystrophic nail. Onychomycosis can infect both fingernails and toenails, but onychomycosis of the toenail is much more prevalent. Discussed in detail in this activity are all evolving facets of the topic, including disease burden, clinical types, staging, diagnosis, and management of toenail onychomycosis. While non-life-threatening, onychomycosis can lead to severe complications such as cellulitis, sepsis, osteomyelitis, tissue damage, and nail loss.
Terbinafine hija medikazzjoni li tiġġieled l-infezzjonijiet fungali billi timblokka squalene epoxidase. Huwa effettiv kontra ħafna tipi ta 'fungi tal-ġilda u huwa approvat għat-trattament tal-fungus tad-dwiefer meta jittieħed mill-ħalq. Filwaqt li l-biċċa l-kbira tal-effetti sekondarji bħall-uġigħ ta 'ras u l-kwistjonijiet tal-istonku huma minuri u jmorru waħedhom, bidliet fit-togħma (disgeusia) jistgħu jvarjaw minn ħfief għal severi, xi drabi jwasslu għal telf ta' piż. Bidliet permanenti fit-togħma huma rari iżda ġew irrappurtati.
Terbinafine is an antifungal medication that works through the inhibition of squalene epoxidase. It has activity against most dermatophytes, and it has approval for use as an oral therapy for the treatment of onychomycosis. Although most side effects are mild and self-limited, such as headache and gastrointestinal symptoms, taste disturbances (dysgeusia) can range from mild to severe, resulting in weight loss, and have rarely been reported permanent.
Terbinafine is an antifungal medication that works through the inhibition of squalene epoxidase. It has activity against most dermatophytes, and it has approval for use as an oral therapy for the treatment of onychomycosis. Although most side effects are mild and self-limited, such as headache and gastrointestinal symptoms, taste disturbances (dysgeusia) can range from mild to severe, resulting in weight loss, and have rarely been reported permanent.
Onychomycosis hija infezzjoni fungali li taffettwa d-dwiefer. Madwar 90% tal-infezzjonijiet tad-dwiefer tas-swaba 'u 75% tal-infezzjonijiet tad-dwiefer tas-swaba' huma kkawżati minn fungi (Trichophyton mentagrophytes, Trichophyton rubrum) . Is-sintomi jinkludu kulur tad-dwiefer, tħaxxin, separazzjoni mis-sodda tad-dwiefer, u tkabbir żejjed. It-trattament tipikament jinvolvi mediċini orali bħal terbinafine jew itraconazole, bi trattamenti topiċi jkunu għażla għal każijiet ħfief għal moderati.
Onychomycosis is a fungal infection of the nail unit. Approximately 90% of toenail and 75% of fingernail onychomycosis are caused by dermatophytes, notably Trichophyton mentagrophytes and Trichophyton rubrum. Clinical manifestations include discoloration of the nail, subungual hyperkeratosis, onycholysis, and onychauxis. Currently, oral terbinafine is the treatment of choice, followed by oral itraconazole. In general, topical monotherapy can be considered for mild to moderate onychomycosis.
Onychomycosis is a fungal infection of the nail unit. Approximately 90% of toenail and 75% of fingernail onychomycosis are caused by dermatophytes, notably Trichophyton mentagrophytes and Trichophyton rubrum. Clinical manifestations include discoloration of the nail, subungual hyperkeratosis, onycholysis, and onychauxis. Currently, oral terbinafine is the treatment of choice, followed by oral itraconazole. In general, topical monotherapy can be considered for mild to moderate onychomycosis.
Il-medikazzjoni antifungali terbinafine meħuda mill-ħalq tidher li hija l-aktar effettiva iżda terbinafine hija assoċjata mal-effett sekondarju tal-fwied.
onikomikożi (onychomysosis) iseħħ f'madwar 10 fil-mija tal-popolazzjoni adulta, b'persuni anzjani affettwati aktar ta' spiss. L-irġiel huma affettwati aktar spiss min-nisa. onikomikożi (onychomysosis) tirrappreżenta madwar nofs il-mard tad-dwiefer. Dan ifisser li d-deformità tad-dwiefer tas-saqajn tista 'tiġi wkoll minn kawżi oħra għajr l-onikomikożi.
○ Trattament - Drogi OTC
Huwa diffiċli li tittratta l-onychomycosis b'mediċini topiċi minħabba li huwa diffiċli li d-drogi jippenetraw id-dwiefer tas-saqajn imħaxxna.
#Ketoconazole
#Clotrimazole
#Miconazole
#Terbinafine
#Butenafine [Lotrimin]
#Tolnaftate
○ Trattament
Ġeneralment ikun meħtieġ trattament fit-tul sakemm id-dwiefer infettat jitneħħa kompletament.
#Terbinafine (oral)
#Itraconazole
#Efinaconazole lacquer [Jublia]
#Ciclopirox lacquer